Selected research
Industry Research
Emerging Cancer Vaccines Industry Research Report 2026
Market perspective
The global Emerging Cancer Vaccines market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Emerging Cancer Vaccines is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Emerging Cancer Vaccines is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Emerging Cancer Vaccines is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Emerging Cancer Vaccines include Merck, GlaxoSmithKline, Northwest Biotherapeutics, Moderna, Avax Technologies and Antigenics, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Emerging Cancer Vaccines market in terms of revenue (US$ million) and, where applicable, sales volume (k units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Emerging Cancer Vaccines Market by Company
Merck
GlaxoSmithKline
Northwest Biotherapeutics
Moderna
Avax Technologies
Antigenics
Emerging Cancer Vaccines Segment by Type
Non Genetic Vaccines
Genetic Vaccines
Emerging Cancer Vaccines Segment by Application
Cancer Research Centers
Cancer Hospital
Clinics
Others
Emerging Cancer Vaccines Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Emerging Cancer Vaccines market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Emerging Cancer Vaccines and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Emerging Cancer Vaccines.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Emerging Cancer Vaccines manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Emerging Cancer Vaccines by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Emerging Cancer Vaccines in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Non Genetic Vaccines
- Genetic Vaccines
Applications
- Cancer Research Centers
- Cancer Hospital
- Clinics
- Others
Companies covered
- Merck
- GlaxoSmithKline
- Northwest Biotherapeutics
- Moderna
- Avax Technologies
- Antigenics
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Emerging Cancer Vaccines Market Size (2021-2032)
- 2.2.2 Global Emerging Cancer Vaccines Sales (2021-2032)
- 2.2.3 Global Emerging Cancer Vaccines Market Average Price (2021-2032)
- 2.3 Emerging Cancer Vaccines by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Non Genetic Vaccines
- 2.3.3 Genetic Vaccines
- 2.4 Emerging Cancer Vaccines by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Cancer Research Centers
- 2.4.3 Cancer Hospital
- 2.4.4 Clinics
- 2.4.5 Others
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Emerging Cancer Vaccines Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Emerging Cancer Vaccines Sales (k units) of Manufacturers (2021-2026)
- 3.3 Global Emerging Cancer Vaccines Revenue of Manufacturers (2021-2026)
- 3.4 Global Emerging Cancer Vaccines Average Price by Manufacturers (2021-2026)
- 3.5 Global Emerging Cancer Vaccines Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Emerging Cancer Vaccines, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Emerging Cancer Vaccines, Product Type & Application
- 3.8 Global Manufacturers of Emerging Cancer Vaccines, Established Date
- 3.9 Global Emerging Cancer Vaccines Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Merck
- 4.1.1 Merck Company Information
- 4.1.2 Merck Business Overview
- 4.1.3 Merck Emerging Cancer Vaccines Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Merck Emerging Cancer Vaccines Product Portfolio
- 4.1.5 Merck Recent Developments
- 4.2 GlaxoSmithKline
- 4.2.1 GlaxoSmithKline Company Information
- 4.2.2 GlaxoSmithKline Business Overview
- 4.2.3 GlaxoSmithKline Emerging Cancer Vaccines Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 GlaxoSmithKline Emerging Cancer Vaccines Product Portfolio
- 4.2.5 GlaxoSmithKline Recent Developments
- 4.3 Northwest Biotherapeutics
- 4.3.1 Northwest Biotherapeutics Company Information
- 4.3.2 Northwest Biotherapeutics Business Overview
- 4.3.3 Northwest Biotherapeutics Emerging Cancer Vaccines Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Northwest Biotherapeutics Emerging Cancer Vaccines Product Portfolio
- 4.3.5 Northwest Biotherapeutics Recent Developments
- 4.4 Moderna
- 4.4.1 Moderna Company Information
- 4.4.2 Moderna Business Overview
- 4.4.3 Moderna Emerging Cancer Vaccines Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Moderna Emerging Cancer Vaccines Product Portfolio
- 4.4.5 Moderna Recent Developments
- 4.5 Avax Technologies
- 4.5.1 Avax Technologies Company Information
- 4.5.2 Avax Technologies Business Overview
- 4.5.3 Avax Technologies Emerging Cancer Vaccines Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Avax Technologies Emerging Cancer Vaccines Product Portfolio
- 4.5.5 Avax Technologies Recent Developments
- 4.6 Antigenics
- 4.6.1 Antigenics Company Information
- 4.6.2 Antigenics Business Overview
- 4.6.3 Antigenics Emerging Cancer Vaccines Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Antigenics Emerging Cancer Vaccines Product Portfolio
- 4.6.5 Antigenics Recent Developments
5 Global Emerging Cancer Vaccines Market Scenario by Region
- 5.1 Global Emerging Cancer Vaccines Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Emerging Cancer Vaccines Sales by Region: 2021-2032
- 5.2.1 Global Emerging Cancer Vaccines Sales by Region: 2021-2026
- 5.2.2 Global Emerging Cancer Vaccines Sales by Region: 2027-2032
- 5.3 Global Emerging Cancer Vaccines Revenue by Region: 2021-2032
- 5.3.1 Global Emerging Cancer Vaccines Revenue by Region: 2021-2026
- 5.3.2 Global Emerging Cancer Vaccines Revenue by Region: 2027-2032
- 5.4 North America Emerging Cancer Vaccines Market Facts & Figures by Country
- 5.4.1 North America Emerging Cancer Vaccines Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Emerging Cancer Vaccines Sales by Country (2021-2032)
- 5.4.3 North America Emerging Cancer Vaccines Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Emerging Cancer Vaccines Market Facts & Figures by Country
- 5.5.1 Europe Emerging Cancer Vaccines Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Emerging Cancer Vaccines Sales by Country (2021-2032)
- 5.5.3 Europe Emerging Cancer Vaccines Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Emerging Cancer Vaccines Market Facts & Figures by Country
- 5.6.1 Asia Pacific Emerging Cancer Vaccines Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Emerging Cancer Vaccines Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Emerging Cancer Vaccines Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Emerging Cancer Vaccines Market Facts & Figures by Country
- 5.7.1 South America Emerging Cancer Vaccines Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Emerging Cancer Vaccines Sales by Country (2021-2032)
- 5.7.3 South America Emerging Cancer Vaccines Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.8 Middle East and Africa Emerging Cancer Vaccines Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Emerging Cancer Vaccines Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Emerging Cancer Vaccines Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Emerging Cancer Vaccines Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Emerging Cancer Vaccines Sales by Type (2021-2032)
- 6.1.1 Global Emerging Cancer Vaccines Sales by Type (2021-2032) & (k units)
- 6.1.2 Global Emerging Cancer Vaccines Sales Market Share by Type (2021-2032)
- 6.2 Global Emerging Cancer Vaccines Revenue by Type (2021-2032)
- 6.2.1 Global Emerging Cancer Vaccines Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Emerging Cancer Vaccines Revenue Market Share by Type (2021-2032)
- 6.3 Global Emerging Cancer Vaccines Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Emerging Cancer Vaccines Sales by Application (2021-2032)
- 7.1.1 Global Emerging Cancer Vaccines Sales by Application (2021-2032) & (k units)
- 7.1.2 Global Emerging Cancer Vaccines Sales Market Share by Application (2021-2032)
- 7.2 Global Emerging Cancer Vaccines Revenue by Application (2021-2032)
- 7.2.1 Global Emerging Cancer Vaccines Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Emerging Cancer Vaccines Revenue Market Share by Application (2021-2032)
- 7.3 Global Emerging Cancer Vaccines Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Emerging Cancer Vaccines Value Chain Analysis
- 8.1.1 Emerging Cancer Vaccines Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Emerging Cancer Vaccines Production Mode & Process
- 8.2 Emerging Cancer Vaccines Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Emerging Cancer Vaccines Distributors
- 8.2.3 Emerging Cancer Vaccines Customers
9 Global Emerging Cancer Vaccines Analyzing Market Dynamics
- 9.1 Emerging Cancer Vaccines Industry Trends
- 9.2 Emerging Cancer Vaccines Industry Drivers
- 9.3 Emerging Cancer Vaccines Industry Opportunities and Challenges
- 9.4 Emerging Cancer Vaccines Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst